Mark Robson
@markrobsonmd.medsky.social
He/him. Medical oncology (breast cancer), girl dad, #medsky, #oncsky. Never leaving NYC. Ever.
Opinions are my own although I remix a lot of ideas so maybe not. Definitely not my employer’s. Nope.
Opinions are my own although I remix a lot of ideas so maybe not. Definitely not my employer’s. Nope.
Pinned
Reposted by Mark Robson
Not everyone can fight Trumpism and Trumpists directly. But remember this: kindness, decency, and fidelity to American values are defiance in the face of Trumpism.
So be kind, decent, and faithful, particularly to the many kinds of people despised and attacked by Trumpists. That’s revolutionary./1
So be kind, decent, and faithful, particularly to the many kinds of people despised and attacked by Trumpists. That’s revolutionary./1
January 20, 2025 at 7:23 PM
Not everyone can fight Trumpism and Trumpists directly. But remember this: kindness, decency, and fidelity to American values are defiance in the face of Trumpism.
So be kind, decent, and faithful, particularly to the many kinds of people despised and attacked by Trumpists. That’s revolutionary./1
So be kind, decent, and faithful, particularly to the many kinds of people despised and attacked by Trumpists. That’s revolutionary./1
Reposted by Mark Robson
The next big thing in Triple Negative Breast Cancer:
VEGF/PD-1 Bispecifics.
Wonderful discussion by Dr. Thomas Grinda on the prospects.
Several Phase III studies planned.
@oncbrothers.bsky.social @sabcs.bsky.social @oncoalert.bsky.social
VEGF/PD-1 Bispecifics.
Wonderful discussion by Dr. Thomas Grinda on the prospects.
Several Phase III studies planned.
@oncbrothers.bsky.social @sabcs.bsky.social @oncoalert.bsky.social
December 11, 2024 at 10:25 PM
The next big thing in Triple Negative Breast Cancer:
VEGF/PD-1 Bispecifics.
Wonderful discussion by Dr. Thomas Grinda on the prospects.
Several Phase III studies planned.
@oncbrothers.bsky.social @sabcs.bsky.social @oncoalert.bsky.social
VEGF/PD-1 Bispecifics.
Wonderful discussion by Dr. Thomas Grinda on the prospects.
Several Phase III studies planned.
@oncbrothers.bsky.social @sabcs.bsky.social @oncoalert.bsky.social
Reposted by Mark Robson
Dr. Waks from @dfcibreastonc.bsky.social presents MARGOT assessing margetuzumab, pertuzumab, taxane versus trastuzumab, pertuzumab, taxane in Stage II/III HER2+ disease.
No statistically significant improvement in pCR.
However, pCR in ER-, HER2+ w/ 12 wks of THP is >70% supporting de-escalation.
No statistically significant improvement in pCR.
However, pCR in ER-, HER2+ w/ 12 wks of THP is >70% supporting de-escalation.
December 11, 2024 at 12:15 AM
Dr. Waks from @dfcibreastonc.bsky.social presents MARGOT assessing margetuzumab, pertuzumab, taxane versus trastuzumab, pertuzumab, taxane in Stage II/III HER2+ disease.
No statistically significant improvement in pCR.
However, pCR in ER-, HER2+ w/ 12 wks of THP is >70% supporting de-escalation.
No statistically significant improvement in pCR.
However, pCR in ER-, HER2+ w/ 12 wks of THP is >70% supporting de-escalation.
Reposted by Mark Robson
Here’s the #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (December 2nd-8th, 2024). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch
December 9, 2024 at 6:05 PM
Here’s the #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (December 2nd-8th, 2024). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch
Reposted by Mark Robson
So excited to share our new paper working w/ David Lyden, Han Kim & Jackie Bromberg (WCM), led by the amazing Inbal Wortzel & Ifé Akano where we revealed a new & unexpected function for chromatin on the surface of exosomes in #cancer #metastasis @ Nature Cancer!
www.nature.com/articles/s43...
www.nature.com/articles/s43...
Unique structural configuration of EV-DNA primes Kupffer cell-mediated antitumor immunity to prevent metastatic progression - Nature Cancer
Lyden and colleagues find that immune developmental genes, such as apoptotic peptidase activating factor 1 (APAF1), support DNA packaging on the surface of tumor-derived extracellular vesicles that ar...
www.nature.com
December 4, 2024 at 2:09 AM
So excited to share our new paper working w/ David Lyden, Han Kim & Jackie Bromberg (WCM), led by the amazing Inbal Wortzel & Ifé Akano where we revealed a new & unexpected function for chromatin on the surface of exosomes in #cancer #metastasis @ Nature Cancer!
www.nature.com/articles/s43...
www.nature.com/articles/s43...
Starting the week in NYC with nuns on bikes!
November 25, 2024 at 2:03 PM
Starting the week in NYC with nuns on bikes!
Reposted by Mark Robson
Let's get ready to be kind: to do our small part in lessen the suffering from hunger hcwvshunger.org amazing work by @tmprowell.bsky.social @shematologist.bsky.social #Oncsky is team #DiagnoseAndTreats The fundraising starts #Thanksgiving day #HCWvsHunger @fumikochino.bsky.social
November 24, 2024 at 11:32 PM
Let's get ready to be kind: to do our small part in lessen the suffering from hunger hcwvshunger.org amazing work by @tmprowell.bsky.social @shematologist.bsky.social #Oncsky is team #DiagnoseAndTreats The fundraising starts #Thanksgiving day #HCWvsHunger @fumikochino.bsky.social
Reposted by Mark Robson
Lesson 1: Do not obey in advance.
Thread of lessons from my book #OnTyranny. Written in 2016.
Thread of lessons from my book #OnTyranny. Written in 2016.
November 23, 2024 at 1:43 PM
Lesson 1: Do not obey in advance.
Thread of lessons from my book #OnTyranny. Written in 2016.
Thread of lessons from my book #OnTyranny. Written in 2016.
Reposted by Mark Robson
Paper looking at rates of accruals to phase 3 clinical trials across disciplines and sizes. Sobering numbers for oncology trials:
Average of 127 sites per trial
Average enrollment of 0.77 patients per month per site.
Trials by top 20 pharma had slower recruitment
www.nature.com/articles/d41...
Average of 127 sites per trial
Average enrollment of 0.77 patients per month per site.
Trials by top 20 pharma had slower recruitment
www.nature.com/articles/d41...
Benchmarking recruitment rates for phase III trials
Discover the world’s best science and medicine | Nature.com
www.nature.com
November 21, 2024 at 12:17 AM
Paper looking at rates of accruals to phase 3 clinical trials across disciplines and sizes. Sobering numbers for oncology trials:
Average of 127 sites per trial
Average enrollment of 0.77 patients per month per site.
Trials by top 20 pharma had slower recruitment
www.nature.com/articles/d41...
Average of 127 sites per trial
Average enrollment of 0.77 patients per month per site.
Trials by top 20 pharma had slower recruitment
www.nature.com/articles/d41...
Reposted by Mark Robson
“We can disagree and still love each other unless your disagreement is rooted in my oppression and denial of my humanity and right to exist”
- James Baldwin
- James Baldwin
November 18, 2024 at 5:15 AM
“We can disagree and still love each other unless your disagreement is rooted in my oppression and denial of my humanity and right to exist”
- James Baldwin
- James Baldwin
Reposted by Mark Robson
Finishing up a trip to Portugal, where I talked on social media in Oncology. I got a question about whether there was an ethical argument for why clinicians should be on social media. My answer: I do think there is an ethical imperative. 1/5
November 16, 2024 at 5:55 AM
Finishing up a trip to Portugal, where I talked on social media in Oncology. I got a question about whether there was an ethical argument for why clinicians should be on social media. My answer: I do think there is an ethical imperative. 1/5
#Medsky friends. I want to give an introduction to LLMs to my groups. Open question for all of you - are there particular ways that you have found LLMs to be helpful? I have a sense of the challenges (hallucination, etc). I’m curious about positive ways people are using them at work.
November 15, 2024 at 7:11 PM
#Medsky friends. I want to give an introduction to LLMs to my groups. Open question for all of you - are there particular ways that you have found LLMs to be helpful? I have a sense of the challenges (hallucination, etc). I’m curious about positive ways people are using them at work.
Reposted by Mark Robson
Reposted by Mark Robson
Hello BlueSky. We had held off starting a dedicated channel to see how BlueSky evolved instead posting all of our 10 Bylines on @bylinesnetwork.bsky.social, but given how fast BlueSky is growing, now is the time to make the jump.
Please help spread the word that Central Bylines are now here
Please help spread the word that Central Bylines are now here
November 13, 2024 at 11:55 PM
Hello BlueSky. We had held off starting a dedicated channel to see how BlueSky evolved instead posting all of our 10 Bylines on @bylinesnetwork.bsky.social, but given how fast BlueSky is growing, now is the time to make the jump.
Please help spread the word that Central Bylines are now here
Please help spread the word that Central Bylines are now here
Reposted by Mark Robson
NEW #Oncology:
EGFR expression mediates resistance to T-DXd (EGFR overexpression ⬇️ HER2 homodimerization & HER2/ADC internalization)
Combining with EGFR mAbs restored HER2/ADC trafficking & ⬆️ activity in nonclinical models
#DrugDevelopment #OncoSky
www.cell.com/cell-reports...
EGFR expression mediates resistance to T-DXd (EGFR overexpression ⬇️ HER2 homodimerization & HER2/ADC internalization)
Combining with EGFR mAbs restored HER2/ADC trafficking & ⬆️ activity in nonclinical models
#DrugDevelopment #OncoSky
www.cell.com/cell-reports...
EGFR-directed antibodies promote HER2 ADC internalization and efficacy
Gupta et al. demonstrate that high EGFR expression mediates resistance to HER2 antibody
drug conjugates (ADCs) including trastuzumab deruxtecan (T-DXd) by limiting HER2/ADC
internalization. The additi...
www.cell.com
November 12, 2024 at 12:33 PM
NEW #Oncology:
EGFR expression mediates resistance to T-DXd (EGFR overexpression ⬇️ HER2 homodimerization & HER2/ADC internalization)
Combining with EGFR mAbs restored HER2/ADC trafficking & ⬆️ activity in nonclinical models
#DrugDevelopment #OncoSky
www.cell.com/cell-reports...
EGFR expression mediates resistance to T-DXd (EGFR overexpression ⬇️ HER2 homodimerization & HER2/ADC internalization)
Combining with EGFR mAbs restored HER2/ADC trafficking & ⬆️ activity in nonclinical models
#DrugDevelopment #OncoSky
www.cell.com/cell-reports...
INAVO120 study: PFS Gains but Added Toxicity: INAVO + PAL-FLV nearly doubled PFS (15 vs. 7.3 mos) in PIK3CA-mutated HR+ HER2- breast cancer. Increased toxicities: 80% had grade 3-4 neutropenia, 5.6% hyperglycemia, 5.6% stomatitis, 3.7% diarrhea, and 6.8% discontinued due to adverse events. #bcsm
November 11, 2024 at 4:49 PM
INAVO120 study: PFS Gains but Added Toxicity: INAVO + PAL-FLV nearly doubled PFS (15 vs. 7.3 mos) in PIK3CA-mutated HR+ HER2- breast cancer. Increased toxicities: 80% had grade 3-4 neutropenia, 5.6% hyperglycemia, 5.6% stomatitis, 3.7% diarrhea, and 6.8% discontinued due to adverse events. #bcsm